Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Oncology 46

Oncology

Gilead/Kite's Yescarta; Roche discards Tecentriq for bladder cancer

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Overwhelming success of Gilead/Kite’s Yescarta; Ridgeback/ Merck in the COVID-19 game; AnaptysBio’s antibody-drug failure; Roche discards Tecentriq for bladder cancer

Gilead's Kite Receives Expanded Approval for its CAR-T Yescarta's in Follicular Lymphoma Gilead’s Kite has successfully secured success in launching the first-ever chimeric antigen receptor (CAR) T-cell therapy in the Follicular Lymphoma Market. The US FDA approved the Yescarta for adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy under accelerated approval. Also known as axicabtagene ciloleucel, Yescarta’s approval is based on the results from the study ZUMA-5. In this single-arm, open-label trial, 91% of patients with r/r FL responded to the treatment, including an estimated 74% of them in continued ...

Explore More...

Therapeutics

PMV Raises; Argos Shares Plummet; Cidara Flunks in; Sarepta Sells to Gilead; Novartis and NHS Ayrshire & Arran launch

Diminishing pipeline of Galectin Inhibitors

TRAIL-Receptor-Agonists

TRAIL Receptor Agonists: Emerging target therapies against Cancer

OncoTrack develops new biomarkers for colon cancer

SEC scrutinizes; Acacia meets endpoint; Axovant’s dementia drug; Novartis expands; Aurobindo responds

Familial Adenomatous Polyposis (FAP): A cataclysmic genetic mutation

FDA approves; Sun Pharma Recalls; Mezzion filed; Sanofi’s antibody to treat

Statistical Insight on Some Common Cancers

Subtypes of cervical cancer identified

Prostate Cancer: Metastases leading to increased incidence in the USA

FDA accepts; Keytruda takes lead; M Pharmaceutical develops; Merck Deploys Palantir

Microbiome- A Living Therapy from Guts to Cancer

Biosimilars: A benchmark in Pharmaceutical Business

Aurobindo takes top generic spot; Valeant unloads Dendreon; Ipsen strikes $1B deal; Takeda shells out $5.2B

mTOR Inhibitors-Emerging therapy in various therapeutic areas

Pfizer uses; FDA approves; EMA approves; Mylan launches

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly